Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;67(2):317-26.
doi: 10.1002/art.38928.

Review: cancer-induced autoimmunity in the rheumatic diseases

Ami A Shah  1 , Livia Casciola-Rosen, Antony Rosen
Affiliations
Review

Review: cancer-induced autoimmunity in the rheumatic diseases

Ami A Shah et al. Arthritis Rheumatol. 2015 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Model for cancer‐induced autoimmunity. Transformation of normal cells (1) may result in gene expression patterns that resemble immature cells involved in tissue healing (2). Occasionally, autoantigens become mutated (3); these are not driver mutations, and not all cancer cells have them. The first immune response is directed against the mutated form of the antigen (4), and may spread to the wild‐type version (5). Immune effector cells directed against the mutant (depicted in red) delete exclusively cancer cells containing the mutation (6). Immune effector cells directed against the wild type (depicted in blue) delete cancer cells without the mutation and also cross‐react with the patient's own tissues (particularly immature cells expressing high levels of antigen, found in damaged/repairing tissue) (7). Once autoimmunity has been initiated, the disease is self‐propagating. Immature cells (expressing high antigen levels) that repair the immune‐mediated injury can themselves become the targets of the immune response, sustaining an ongoing cycle of damage/repair that provides the antigen source that fuels the autoimmune response.
See this image and copyright information in PMC

References

    1. Schreiber RD, Old LJ, Smyth MJ.Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.Science 2011;331:1565–70. - PubMed
    1. Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer 2012;12:742–64. - PMC - PubMed
    1. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola‐Rosen LA, Wigley FM, et al.Association of the autoimmune disease scleroderma with an immunologic response to cancer.Science 2014;343:152–7. - PMC - PubMed
    1. Shah AA, Rosen A, Hummers L, Wigley F, Casciola‐Rosen L.Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.Arthritis Rheum 2010;62:2787–95. - PMC - PubMed
    1. Abu‐Shakra M, Guillemin F, Lee P.Cancer in systemic sclerosis.Arthritis Rheum 1993;36:460–4. - PubMed

Publication types

MeSH terms